trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Abnormal brain cholesterol metabolism is associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
7 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that abnormal brain cholesterol metabolism is associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease?

Yes. Abnormal brain cholesterol and lipid metabolism is strongly linked to the pathogenesis of neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.

Verdict: SUPPORTED · 7 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently demonstrate that lipid dysregulation, including altered cholesterol homeostasis and trafficking within the central nervous system and astrocytes, plays a fundamental role in driving neurodegeneration in conditions such as Alzheimer's and Parkinson's diseases. There are no papers refuting this association.

Evidence for · 7
Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.
2026
Reviews lipidomics and metabolic alterations associated with GBA1-related Parkinson's disease pathology.
Get citation
Y, N., H, C., Y, S., & W, L. (2026). Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.. doi.org. https://doi.org/10.1186/s13024-026-00931-7

See more details
More for · 6
Lysosomal homeostasis at the crossroads of neurodegeneration.
2026
Identifies lipid imbalance and lysosomal dysfunction as common denominators underlying Alzheimer's and Parkinson's diseases.
Get citation
S, D. T. & SA, T. (2026). Lysosomal homeostasis at the crossroads of neurodegeneration.. doi.org. https://doi.org/10.1172/jci199845

Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.
2026
Demonstrates systemic lipid dysregulation in Parkinson's disease patients.
Get citation
M, D. P., M, B., G, P., & R, C. (2026). Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.. doi.org. https://doi.org/10.3390/ijms27093711

PCSK9 in bridging metabolism and neurodegeneration: a new paradigm for alzheimer's treatment.
2026
Explores how PCSK9-mediated cholesterol dyshomeostasis links metabolic dysfunction to Alzheimer's disease pathology.
Get citation
S, S., S, S., & TG, S. (2026). PCSK9 in bridging metabolism and neurodegeneration: a new paradigm for alzheimer's treatment.. doi.org. https://doi.org/10.1007/s11011-026-01900-1

Astrocytic lipid dysregulation as an early driver of neurodegeneration.
2026
Highlights astrocytic lipid and cholesterol dysregulation as an early driver of neurodegeneration across multiple disorders.
Get citation
WS, K. & GM, H. (2026). Astrocytic lipid dysregulation as an early driver of neurodegeneration.. doi.org. https://doi.org/10.1038/s41582-026-01238-3

Cholesterol crystal formation and embolism in the central nervous system and their potential role in Alzheimer's disease.
2026
Examines the role of central and systemic cholesterol crystal formation in brain pathology and Alzheimer's disease.
Get citation
A, H., FNU, P., M, S., R, S., V, K., IA, P., MB, G., JV, B., M, Y., & GS, A. (2026). Cholesterol crystal formation and embolism in the central nervous system and their potential role in Alzheimer's disease.. doi.org. https://doi.org/10.1016/j.ahjo.2026.100826

β-sitosterol and next-generation neuroprotection for multi-target strategies and the gut-brain axis in neurodegenerative diseases.
2026
Discusses phytochemicals that target cholesterol homeostasis to ameliorate Alzheimer's and Parkinson's disease mechanisms.
Get citation
AM, S. (2026). β-sitosterol and next-generation neuroprotection for multi-target strategies and the gut-brain axis in neurodegenerative diseases.. doi.org. https://doi.org/10.1016/j.jsbmb.2026.107080

What does the evidence say?

The retrieved papers consistently demonstrate that lipid dysregulation, including altered cholesterol homeostasis and trafficking within the central nervous system and astrocytes, plays a fundamental role in driving neurodegeneration in conditions such as Alzheimer's and Parkinson's diseases. There are no papers refuting this association.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work